Skip to content
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces New Article Published in Cancer Cytopathology Detailing Clinical Utility of Its RNA Sequencing-Based Testing for Thyroid Cancer Diagnosis and Treatment
- Testing by Afirma GSC and Afirma XA helps reduce unnecessary surgeries and inform disease treatment - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 17, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced today that a review article in Cancer Cytopathology , a journal of the American Cancer
Toggle Summary Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 10, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced today that findings from a new real-world study show that the company’s Afirma ® Genomic Sequencing Classifier (GSC) helps to identify significantly more benign thyroid nodules and further reduce


Date Event Details
Summary Toggle Jun 6, 2019 9:00 AM EDT
Jefferies 2019 Global Healthcare Conference
Summary Toggle Jun 5, 2019 2:00 PM CDT
The William Blair 39th Annual Growth Stock Conference


Title Documents

Corporate Presentation June 2019